Chulin Sha
Overview
Explore the profile of Chulin Sha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li T, Liu X, Qian H, Zhang S, Hou Y, Zhang Y, et al.
Nat Commun
. 2024 Aug;
15(1):6751.
PMID: 39117705
Despite the well-established significance of transcription factors (TFs) in pathogenesis, their utilization as pharmacological targets has been limited by the inherent challenges in modulating their protein interactions. The lack of...
2.
Li B, Wang Z, Liu Z, Tao Y, Sha C, He M, et al.
Brief Bioinform
. 2024 Jul;
25(4).
PMID: 38975893
The process of drug discovery is widely known to be lengthy and resource-intensive. Artificial Intelligence approaches bring hope for accelerating the identification of molecules with the necessary properties for drug...
3.
Wang Z, Feng Z, Li Y, Li B, Wang Y, Sha C, et al.
Brief Bioinform
. 2023 Nov;
25(1).
PMID: 38033291
Although substantial efforts have been made using graph neural networks (GNNs) for artificial intelligence (AI)-driven drug discovery, effective molecular representation learning remains an open challenge, especially in the case of...
4.
Davies J, Hilton L, Jiang A, Barrans S, Burton C, Johnson P, et al.
Blood Adv
. 2023 Aug;
7(20):6156-6162.
PMID: 37595057
No abstract available.
5.
Davies A, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al.
J Clin Oncol
. 2023 Mar;
41(15):2718-2723.
PMID: 36972491
JCO The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by...
6.
Bewicke-Copley F, Korfi K, Araf S, Hodkinson B, Kumar E, Cummin T, et al.
Blood Adv
. 2022 Aug;
7(5):845-855.
PMID: 35947123
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse...
7.
Ahmed S, Glover P, Taylor J, Sha C, Care M, Tooze R, et al.
Br J Haematol
. 2020 Nov;
192(3):599-604.
PMID: 33249557
Cell-of-origin subclassification of diffuse large B cell lymphoma (DLBCL) into activated B cell-like (ABC), germinal centre B cell-like (GCB) and unclassified (UNC) or type III by gene expression profiling is...
8.
Cucco F, Barrans S, Sha C, Clipson A, Crouch S, Dobson R, et al.
Leukemia
. 2019 Dec;
34(5):1329-1341.
PMID: 31844144
Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched...
9.
Davies A, Cummin T, Barrans S, Maishman T, Mamot C, Novak U, et al.
Lancet Oncol
. 2019 Apr;
20(5):649-662.
PMID: 30948276
Background: Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell of origin, corresponding to germinal centre or activated B cell. We...
10.
Sha C, Barrans S, Cucco F, Bentley M, Care M, Cummin T, et al.
J Clin Oncol
. 2018 Dec;
37(3):202-212.
PMID: 30523719
Purpose: Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt lymphoma is well known....